Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

PCSK9抑制剂的使用正在为临床上难治性高胆固醇血症以及他汀类药物不耐受的患者群体开辟全新的治疗前景。 1月10日，恒瑞医药的一款抗PCSK9药物瑞 ...

1月10日，恒瑞医药的一款抗PCSK9药物瑞卡西单抗获国家药监局批准上市，成为最新一款获批上市的国产靶向PCSK9的降脂药物。此前，已有6款PSCK9药物 ...

对此，近年来备受瞩目的PCSK9单抗类药物与他汀类药物的联合治疗方案应用越来越广泛，但在给药频率上仍存在一定局限性，患者需要每日服用他汀 ...

To understand the full scope of this medication -- its effectiveness, risks, and who stands to benefit the most -- ...

Injectable antibodies targeting PCSK9 have failed to take off as expected ... given as once- or twice-monthly monthly injections – were hailed as blockbusters-in-waiting when they launched ...

There are two antibodies already on the market that target PCSK9 – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but these require subcutaneous injection every ...

Though injection site reactions like redness and itchiness are common, few people have had to stop either PCSK9 inhibitor because of them.

They found that the constructs quickly and effectively silenced Pcsk9, leading to an approximate 35 percent reduction in bad cholesterol in comparison to mice who had received a sham injection ...

PCSK9 inhibitors are a new class of medications ... Also, these medications are only available as an injection. They have to be given every 2 to 4 weeks, and you have to go to your doctor ...